Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Virginia Commonwealth University
Washington University School of Medicine
Incyte Corporation
Children's Oncology Group
Cedars-Sinai Medical Center
BPGbio
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
Cedars-Sinai Medical Center
Seattle Children's Hospital
University Hospital, Basel, Switzerland
Celgene
National Cancer Institute (NCI)
Children's Hospital Los Angeles
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Children's Hospital Medical Center, Cincinnati
Celgene
University College, London
Northwestern University
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Celgene
National Institutes of Health Clinical Center (CC)
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
British Columbia Cancer Agency
Albert Einstein College of Medicine
Radiation Therapy Oncology Group
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
AHS Cancer Control Alberta
SillaJen, Inc.
Children's Oncology Group
Duke University
University of California, San Francisco
St. Jude Children's Research Hospital
University of California, San Francisco
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Indiana University